Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 811

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 811
---
 in a private placement offering of (i) 5,194,802 common shares at a purchase price of $0.77 per share, and (ii) warrants to purchase up to an aggregate of 2,597,401 common shares at an exercise of $0.70 per share. The Company’s Chairman of the Board of Directors, Ronald Hafner, purchased 324,675 common shares in the offering and the Company’s Chief Medical Officer, George Apostol, purchased 1,298,701 common shares in the offering. The Company engaged Laidlaw to serve as the placement agent for the Company in connection with the above -describedoffering. The Company paid Laidlaw a cash placement of USD 140,000for the securities sold in the offering. At the closing of the October 2022 offering, the Company’s existing convertible short -termnotes, with an aggregate principal balance of $ 1,530,000plus all accrued interest, that were issued in August 2022, were automatically converted into 2,516,429common shares and the holders received warrants to purchase up to 1,258,215common shares with an exercise price of $ 0.70, that are exercisable six months after their issuance and will expire five years following the date that the warrants are initially exercisable, and are otherwise substantially similar to the form of the common warrants. On April 25, 2022, the Company closed a registered direct offering with healthcare focused institutional investors alongside participation from Mr. Hafner, for the purchase and sale of (i) 3,015,384common shares, at a purchase price of $ 1.04per share, and (ii) pre -fundedwarrants to purchase up to 1,184,616common shares at a purchase price of $ 1.04minus CHF 0.02per pre -fundedwarrant. Mr. Ronald Hafner, purchased 95,984of the 3,015,384common shares in the offering. In a concurrent private placement, the Company issued the investors, who also participated in the registered direct offering, warrants to purchase up to 3,150,000common shares. The warrants have an exercise price of $ 1.04per common share, are exercisable six months following the date of issuance and expire 5 years following the initial exercise date. Pursuant to the terms of the securities purchase agreement, dated April 13, 2022, between